BioLegend Neuroscience
Unlocking the biology of the brain is a research imperative that has garnered much attention from public and private entities in recent years. For example, the BRAIN Initiative and EU Initiative (humanbrainproject.eu) are focused on innovative research and technology that increases our understanding of the brain. Neurodegenerative diseases already constitute a public health and economic crisis, and as the population ages, the urgent need for better treatments for these diseases is intensified. With the acquisition of the Covance antibody product portfolio, BioLegend signaled its commitment to enabling legendary discovery within the neuroscience research community. BioLegend is making further investments in the portfolio, becoming a leading provider of reagents known for quality and innovation, and helping scientists advance the understanding of brain biology, interrogate their pathways, and identify potential biomarkers that may improve the success of clinical programs for neurodegenerative diseases.
Enabling Legendary Discovery in Neuroscience   Product Categories   Featured Content   Citations   Product Reviews
This content requires opt in of marketing cookies.
Open with YouTubeChange your cookie preferences
News and Events

01/30/2018
NIH and Michael J. Fox Foundation Announce Partnering Program for Parkinson’s Disease Research

The NIH and the Michael J. Fox Foundation have announced a partnership program along with biopharmaceutical and life science companies that will focus on disease markers for Parkinson’s Disease progression as part of the NIH Accelerating Medicines Partnership (AMP). BioLegend is proud to be a participant and sponsor for the MJFF-led Parkinson’s Progression Markers Initiative (PPMI), which will contribute data and samples for the program. Our LEGEND MAX™ Human α-Synuclein ELISA kit has been used extensively in PPMI’s multi-centered studies for the measurement of α-Synuclein in biological samples. 

Read the NIH press release, the MJFF press release, and learn more about the MJFF Parkinson’s Progression Markers Initiative.



06/02/2017
BioLegend Synaptic Biology Antibody Price Reduction

BioLegend is continually striving to provide top quality reagents to support neuroscience research. Our extensive catalog contains a wide selection of antibodies that recognize targets relevant in Synaptic Biology. We are committed to offering these products at a great value to our customers in an effort to accelerate research and discovery in this area. To this end, we are pleased to announce a permanent price reduction of up to 40% on over 70 targets in this category. Take advantage of this offering and submit a product review from this selection of antibodies to receive a $25 Amazon gift card.

Learn More



Sponsored Webinars

This content requires opt in of marketing cookies.
Open with YouTubeChange your cookie preferences
This content requires opt in of marketing cookies.
Open with YouTubeChange your cookie preferences
This content requires opt in of marketing cookies.
Open with YouTubeChange your cookie preferences
Login/Register
Forgot your password? Reset Password
Request an Account